Brief: Oncolytics Biotech Inc reports qtrly share of $0.02
Nov 8 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* Oncolytics Biotech Inc. announces 2017 third quarter
results
* At September 30, 2017, company reported $14.0 million in
cash
and cash equivalents; cash runway expected to end of 2018
* Oncolytics Biotech Inc qtrly basic and diluted loss per
common
share $0.02
Source text for Eikon: ID:nPn1gPP1ba
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer